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Common features of arthritis include destruction of extracellular matrices in cartilage and 
bone as a result of chronic inflammation. Cartilage deterioration is generally described as a 
result from the effect of immune cells and their inflammatory mediators. However, recent 
reports suggest a role of chondrocytes in the initiation of inflammation in joints, and that they 
play a pivotal role in the destruction of their own matrix. Chondrocytes express multiple 
immune receptors and can produce and bind several cytokines, thus rendering them possible 
targets for therapy. We have demonstrated that serially cultured human articular chondrocytes 
posses the Chemerin receptor, ChemR23, and that this receptor is also present on 
chondrocytes in native human cartilage. In cultured chondrocytes we detected mRNA for the 
Chemerin receptor, and observed that stimulation with Chemerin resulted in phosphorylation 
of p44/p42 MAPK and Akt. Moreover, the Chemerin stimulation resulted in a marked 
increase of the pro-inflammatory cytokines IL-6 and IL-8, a modest increase in TNF- and 
IL-1, and marked increase in MMP-2, MMP-3 and MMP-13 in the culture supernatants. 
These results show that ChemR23 conveys pro-inflammatory signalling and affects MMP 
production when binding its ligand Chemerin. These observations indicate that ChemR23 
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Joint disease arises and develops mainly from arthritis, also termed joint inflammation. 
Arthritis comprises a group of conditions leading to damage of the joints and these conditions 
are often called articular degenerative inflammatory diseases [1]. Arthritic conditions include 
the diseases osteoarthritis, rheumatoid arthritis, psoriasis arthritis, septic arthritis and gout, 
however osteoarthritis (OA) and rheumatoid arthritis (RA) are the two most common types of 
arthritis world wide [2] 
 
The symptoms associated with OA are significant functional impairment and signs and 
symptoms of inflammation like pain, stiffness, swelling and loss of mobility. The risk of  
developing OA increases with age and the risk factors include obesity, injury, previous 
surgery and overload to the joints [3]. RA is considered an autoimmune disease where the 
immune system attacks the bodies own cells and tissues. This results in  a chronic articular 
disease where inflammation causes destruction of cartilage and bone [4]. Considering the 
different aetiology of arthritic conditions, inflammatory joint diseases represent a 
heterogeneous group of disorders that share features of deteriorated extra cellular matrices in 
articular cartilage and bone. Arthritis affects all structures within a joint, not only is articular 
cartilage lost, but bone remodelling occurs with capsular stretching and weakness of 
periarticular muscles [3]. 
 
Arthritis results in the release of inflammatory mediators in the synovial fluid and synovium 
that directly and indirectly influence cartilage homeostasis [5]. Recent studies show that 
chondrocytes in the cartilage actively participates in the disease process, and especially in the 
molecular signalling that occurs. Chondrocyte activity includes receptor signalling, 
production of matrix metalloproteinases (MMP), cytokines, and cell proliferation [5]. Studies 
of early RA show that cartilage destruction is not only a result of inflammation mediated by 
immune cells, but may in part be caused by the chondrocytes themselves; this is apparent in 
early cases of OA where cartilage destruction occurs without overt clinical signs of 




1.1 Synovial Joints 
Human joints are classified according to structure and function; how the bones are connected 
to each other and the degree of movement between the articular bones. Classified by structure 
humans have; fibrous joints connected by fibrous connective tissue, cartilaginous joints joined 
by cartilage, and synovial joints where the bone is not directly joined. Synovial joints are the 
most common and moveable joints in the human body and include; wrist, elbow, thumb, 
shoulder, hip and knee. In humans the knee joint supports nearly the entire body weight, thus 
being vulnerable to acute injury and arthritis [8]. 
 
The articular surfaces of synovial joints are covered by a thin layer of hyaline cartilage up to 3 
mm thick. A viscous and clear synovial fluid lubricates the hyaline cartilage, supplying 
essential nutrients to the chondrocytes. A normal knee will have approximately 2 ml of 
synovial fluid that normally contains around 100 cells/mm3, these cells are mostly 
lymphocytes and macrophages. Synovial joints are enclosed by a fibrous capsule which is 
lined by a thin synovial membrane. The synovial membrane comprises to cell types; modified 
macrophages (synoviocytes type A) and fibroblast-like cells (synovicytes type B), these cells 
synthesize and secrete hyaluronic acid and proteins of the synovial fluid. The fibrous capsule 
of the joint and the bone underlying the articular surface contains several sensory nerve 
endings. In contrast, the synovial membrane has no specialised sensory receptors and is 




Figure 1: Human synovial joint 
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1.2 Hyaline cartilage 
Hyaline cartilage is a firm and flexible connective tissue, and is specialised to absorb and 
resist compression. The tissue is supported by underlying bone and lubricated and nurtured by 
the synovial fluid. Nutrition and waits disposal has to be transported by diffusion through the 
synovial fluid due to the absence of blood vessels and lymphatic-drainage in the cartilage. The 
cells present in the cartilage are chondrocytes, and are contained in cavities in the matrix 







Figure 2: Histology section of hyaline articular cartilage.  
 
Chondrocytes synthesize and secrete macromolecules that constitute the cartilage matrix. 
Chondrocytes replenish the matrix as the macromolecules turn over, but their ability to 
remodel and repair the matrix is rather limited. The extracellular material consists of large 
hydrated proteoglycan aggregates, trapped within a matrix of type II collagen fibrils. The 
entrapped proteoglycans, mainly aggrecan, are composed of a core protein that forms a 
backbone, which glycosaminoglycan (GAG) chains are covalently attached to. These chains 
extend from the backbone in a brush-like structure that allows trapping of water molecules 
(Fig. 3). The GAGs are negatively charged and generate large osmotic swelling pressures that 
produce a hard compression-resistant substance. The three major GAGs found in cartilage are 
chondroitin sulphate, keratan sulphate and hyaluronan. Numerous chains of chondroitin 










The immune system can be classified as innate (non-specific) and adaptive (specific). The 
innate system is the first line defence against pathogens and participants are cellular and non-
cellular components like the complement system, epithelial cells, polymorphonuclear 
leukocytes (PMN), mononuclear cells, and conserved innate immune receptors like the Toll-
like receptors (TLR). In the innate immune system, phagocytes and soluble factors 
unspecifically eliminate or neutralize pathogens [10]. The adaptive immune system involves 
building immunity over several days and is based on specificity and memory, characterized 
by antibody production and lymphocyte activation. Whenever the innate immune system is 
unsuccessful, the adaptive system will be initiated in the lymphoid organs, where mature 
dendritic cells (DCs) or macrophages present antigens to naive or memory T-cells [11]. 
 
The innate immune system initiates’ acute inflammation in response to tissue injury and the 
usual outcome is successful resolution, destruction of invading microorganisms, prevention of 
spread, and promotion of subsequent damage repair. The acute inflammation is often 
characterized by the rapid influx of PMNs, typically neutrophils, followed by monocytes that 
mature into inflammatory macrophages that proliferate. Resolution of inflammation occurs 
when the neutrophils are eliminated and the tissue macrophages returns to normal pre-
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inflammatory numbers and phenotypes [12]. When resolution fails, the acute inflammation 
may develop in to a chronic phase which may distort the tissues and cause permanent damage. 
 
Inflammation involves interaction with the microvasculature, circulating blood cells and cells 
in affected tissues. These cells can synthesize and secrete a variety of soluble substances 
termed inflammatory mediators. Such mediators include cytokines and eicosanoids. Cytokines 
are peptides or glycoproteins that bind receptors on the surface of their target cells. Cytokines 
affects nabouring cells on the site of their production (paracrine action), on the cells that 
produce them (autocrine action), and they can affect multiple cell types, thus cytokines can be 
considered as signals alerting the immune system, conveying communication between the 
cells. Despite the beneficial role of inflammatory mediators in host defence, their sustained 
production can lead to serious, chronic pathological conditions, such as atherosclerosis and 
arthritis [13]. In chronic inflammation, the production of cytokines and proteases by 
infiltrating- and resident-cells, escape regulatory mechanisms. The imbalance between these 
mediators and their respective inhibitors is responsible for the persistence of chronic 
inflammatory conditions and may even be necessary for the initiation of chronic inflammation 
[14]. 
 
1.4 Joint inflammation and cartilage destruction 
Joint inflammation  in RA affects primarily the synovial lining of the joints, and the 
inflammatory process is characterized by proliferating synovial cells, increased 
vascularization, and infiltration of inflammatory cells [15]. In later stages there is an extension 
of the inflammatory tissue mass to the articular cartilage with progressive overgrowth of the 
aticular surface, and tongues of proliferating cells can be seen penetrating the extracellular 
matrix of the cartilage, commonly described as pannus. The RA synovium produces a variety 
of mediators capable of stimulating cartilage matrix destruction and states a connection 
between inflammation and the development of joint damage. However, joint destruction may 
progress in spite of attenuated inflammatory activity, and cartilage and bone erosion may 
develop in the absence of overt clinical signs of inflammation [7].  
 
OA is not recognized as a classical inflammatory arthropathy [16] , and although there are 
debates regarding the essential role of synovial inflammation in OA, overexpression of pro-
inflammatory mediators are common in early and late OA. In OA, synovial inflammation also  
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contributes to dysregulation of chondrocyte function, favouring imbalance between the 
catabolic and anabolic activities of the chondrocyte in remodelling the extracellular matrix 
[16].  
 
Studies in humans and animals indicate that although the specific cellular mechanisms of 
cartilage destruction are not clarified, TNF-, IL-1 and other pro-inflammatory cytokines 
appears to drive the process [4]. In RA the cartilage destruction can be explained by the 
release of proteinases by synovial cells capable of digesting the cartilage matrix components, 
along with the inflammatory cells that release inflammatory mediators in the synovial fluid. 
Yet, there is evidence of loss of proteoclygans and selective damage to type II collagen in the 
middle and deep zones of the cartilage [6] suggesting that the chondrocytes degrades its own 
matrix. Recent evidence suggest potential candidates responsible for cartilage destruction to 
be different MMPs which degrade collagens and proteoglycans [17]. MMPs are produced by 
both the synovium and chondrocytes in response to inflammatory cytokines, and it has been 
demonstrated that the pro-inflammatory cytokine IL-1 up-regulates the expression of several 
genes in chondrocytes, including MMP transcripts [17, 18]. Chondrocytes may not only 
participate in the destruction of the cartilage matrix by responding to pro-inflammatory 
cytokines, but can also contribute by producing pro-inflammatory cytokines themselves. This 
way, chondrocytes exert autocrine and paracrine effects increasing tissue catabolism and 
suppressing anabolic repair processes [5].  
 
1.5 Chemokines 
Antigen presenting cells (APCs) like the DCs and macrophages control the gateway between 
innate and adaptive immunity, thus APCs play a major role in chronic inflammatory diseases. 
APCs are activated by microorganisms through Toll-like receptors and release co-stimulatory 
molecules, cytokines and chemokines, thus being part of the innate immune system. The 
APCs further mounts the adaptive immune response by antigen presentation and T-cell 
activation [19]. APCs are attracted to infection- and inflammation-sites by a variety of factors, 
among which chemokines are the largest group so far [20]. Chemokines are generally 
classified as cytokines that control cell trafficking. In humans the chemokines are abundant, 
including more than 50 different types that can be separated into four families according to 
the location of their cysteine residues and their function [10]. The four chemokine groups are 
CC, C, CXC and CX3C, where C is a cysteine and X any amino acid residue. The largest 
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family consists of CC chemokines which attracts mononuclear cells to sites of chronic 
inflammation, monocyte chemoattractant protein 1 (MCP-1) is a classical example of a CC 
chemokine. The second largest family consists of the CXC chemokines which attract PMNs 
to sites of acute inflammation, an example here is interleukin-8 (CXCL8) [10]. Functionally, 
chemokines can be divided into inflammatory, haemostatic, and dual function. Inflammatory 
chemokines are induced by pathogens, cytokines and growth factors, and recruit effector 
leukocytes to sites of infection, inflammation, tissue injury and tumours [21].   
 
The chemokines affect cells through surface bound chemokine receptors, these are seven 
transmembrane helical segments coupled to a G-protein that transduces intracellular signals. 
Chemokine receptors belongs to class A of the G-protein coupled receptor (GPCR) super 
family, and are rhodopsin-like receptors that span the membrane seven times and are coupled 
to heterotrimeric G proteins [21]. Each chemokine receptor may have multiple ligands, 
thus several chemokines can bind different receptors and activate intracellular pathways with 
similar cellular responses [22]. The chemokine characteristics and the chemokine receptors 
involvement in leukocyte recruitment to inflammatory sites has rendered them attractive 
targets for therapeutic applications [23]. 
 
In the context of arthritis, synovial tissue and synovial fluid from RA patients contain 
increased concentrations of multiple chemokines, and the inflammatory cells that infiltrate the 
joint express respective chemokine receptors [24]. Several studies show increased levels of 
multiple chemokines in RA compared to OA, and this may reflect different inflammatory 
activity in the two conditions [25, 26]. The chemokine production in RA is mainly a product 
of macrophages and synoviocytes, however, studies show that chondrocytes can produce 
chemokines as well [22, 27]. Chemokines produced in the joint recruit leukocytes into the 
joint cavity and stimulate chondrocytes and synovial cells to release inflammatory mediators, 








1.6 G-protein coupled receptor- ChemR23 
ChemR23 is a Gi linked, G-protein coupled receptor, also called Chemokine-Like Receptor 
1 (CMKLR1). ChemR23 exhibits homology to chemokine receptors although it is not 
classified within the chemokine receptor family [28]. Most chemoattractant molecules are 
characterized by a relatively poor selectivity, as they usually attract a diverse set of 
leukocytes. Within the leukocyte population, ChemR23 is rather specific, being expressed 
mainly in macrophages and plasmacytoid DCs, the two major classes of APCs [23]. 
Additionally, the receptor was identified in 2007 on CD56lowCD16+ natural killer (NK) cells 
[29], and due to the receptors role in co-localization of NK celles, DCs and machrophages, 
both the receptor and its ligand represent attractive candidates for future drug development.    
 
ChemR23`s natural ligand Chemerin, was identified in 2003 by Wittamer et al. where the 
authors described Chemerin as a potent chemoattractant factor for ChemR23 positive cells, 
thus attracting APCs [19]. Chemerin is initially synthesized and secreted as pro-Chemerin, an 
inactive form of the peptide. Chemerin is a potent ligand for ChemR23 when proteolytic 
removal of the last six amino acids at the C-terminal end occurs. Active Chemerin is present 
in plasma, serum and hemofiltrate, and the estimated concentration in plasma and serum in 
humans are 3.0 and 4.4 nM, respectively [30]. Chemerin is present in several tissues including 
liver, pancreas and lungs, and are abundant in inflammatory fluids [19]. According to 
Wittamer et al. activated neutrophils in the early phase of inflammation releases serine 
proteases cathepsin G and human leukocyte elastase, and these proteases mediate the 
conversion of pro-Chemerin into active Chemerin. Hence, the Chemerin may have a potential 
role as a link between innate and adaptive immunity by attracting APCs when activated by 
neutrophils [23]. Zabel et al. showed in 2005 that also serine proteases of the coagulation- and 
fibrinolytic-cascades activates Chemerin, thus implicating the involvement of Chemerin in 





Figure 4: Chemerin activation by multiple serine protease-mediated pathways triggered by 
injury, inflammation or infection [31] 
 
Chemerin was first described as a pro-inflammatory plasma peptide based on its ability to 
induce immune cell migration; however Cash et al. has in 2008 shown that murine Chemerin 
also can exhibit anti-inflammatory effects on macrophages. According to the latter authors, 
activated macrophages may be capable of converting Chemerin into a potent anti-
inflammatory peptide by cysteine proteases calpains and cathepsin S. They show that 
designed Chemerin peptides can bind macrophages and inhibit the production of pro-
inflammatory cytokines such as TNF-, IL-1, IL- 6, IL-12 and RANTES, and increase the 
production of anti-inflammatory cytokines like TGF- and IL-10 [13]. Cash et al. thereby 
postulates that enzymatic proteolysis of pro-Chemerin can result in the generation of both 
activating and inhibitory peptides. Whereas serine proteases capable of producing activating 
peptides are released from activated neutrophils [23], cycteine proteases that generate 
inhibitory peptides, are released from activated elicited macrophages [13].  
 
Several research groups have described a role of Chemerin in adipogenesis and adipocyte 
metabolism, and characterize Chemerin as a novel adipokine [32-34]. Their results contradict 
previous reports where ChemR23 is stated to be expressed only by macrophages, NK cells 
and plasmacytoid DCs. According to Goralski et al. Chemerin and its receptor are expressed 
in human adipocytes which indicate that white adipose tissue is both a source and a target for 
Chemerin [33]. Furthermore, it has been observed that adiposity associated with obesity 
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induces inflammation in adipose tissue which may correlate to the chemotactic ability of 





Figure 5: Secreted Chemerin may mediate recruitment of ChemR23 (CMKLR1)-expressing cells 
(e.g. machrophages and DCs) to adipose tissues [33]. 
 
 
1.7 Receptor signalling 
As previously described, ChemR23 is a member of the seven-helix receptor family also called 
G-protein coupled receptor super family (serpentine receptors). Common for these receptors 
is the transfer of signals with the help of G-proteins to effector proteins that alters the 
concentration of ions and second messengers inside the cell (Fig. 6). The G-protein involved 
in ChemR23 signalling consists of three subunits (,  and ) where the -subunit can bind 
GDP or GTP and has GTPase activity. The G-proteins can be divided into: stimulatory G-
proteins (Gs), which activate adenylate cyclases or influence ion channels; inhibitory G-
proteins (Gi), which inhibit adenylate cyclases; and the Gq proteins, which activates the 
effector enzyme phospholipase c. Binding of ligand to the 7-helix receptors alters the receptor 
confirmation in such a way that the G-protein can attach on the inside of the cell. This 
attachment causes the -subunit to exchange bound GDP for GTP which releases the G 
protein from the receptor, and thereafter the G protein dissociates into a -subunit and a -
unit. Both units bind other membrane proteins and alter their activity: ion channels can be 





Figure 6: Schematic overview of 7-helix receptor signalling [35] 
 
 
The ChemR23 is a Gi coupled receptor where the Gi proteins inhibit adenylate cyclase 
activity. Activation of the receptor on macrophages and DCs, results in intracellular calsium 
release, inhibition of cAMP accumulation, phosphorylation of p42-p44 MAP kinases (ERK 
1/2) and elevated levels of the transcription factor NF-B. In macrophages and DCs, this 
intracellular pathway creates a pro-inflammatory profile with the initiation of pro-
inflammatory transcripts [19]. Zabel et al has newly identified an orphan receptor on mast 
cells, CCRL2, which binds Chemerin as well. However, this receptor does not conduct 
intracellular signalling when Chemerin binds, although local concentration of Chemerin is 
increased [36]. It might be that this receptor functions as a decoy receptor, neutralizing 





2. Aim of study 
 
The current medical treatment of joint disease is predominantly based on anti-inflammatory 
therapy where inflammatory cells and their mediators are targeted. Less attention has been 
given to the chondrocytes and their potential as a therapeutic target for preventing cartilage 
destruction. Marked levels of active Chemerin are present in inflammatory fluids, and also in 
synovial fluid from inflamed joints. Given recent evidence showing that chondrocytes 
participate in cartilage degradation, and the fact that active Chemerin is present in synovial 
fluid, we put forward a hypothesis that chondrocytes express ChemR23, and that Chemerin 
binds and activates the receptor to affect cartilage metabolism through MMP- and cytokine-
production.  
 
The specific aims of the study were: 
1. To show that chondrocytes express ChemR23 receptor 
2. To show that ligand binding of the receptor leads to activation of intracellular 
signalling mechanisms.  
3. To show that Chemerin stimulate the chondrocytes to produce pro-inflammatory 


















3. Materials and methods 
 
3.1 Acquisition of chondrocytes 
Patients undergoing autologous chondrocyte transplantation (ACT) gave their informed 
consent for use of surplus cells from the transplantation programme. The patients, aged 25-45 
suffered either from focal cartilage damage in knee joints or late stages of OA. Biopsies were 
taken from the articular surface at a low-weight bearing area of the joint and thereafter 
enzymatically digested [37]. The cells were serially passaged for 3 weeks to obtain a 
sufficient cell number and surplus cells were cryo-preserved for experiments. 
 
3.2 Culture medium 
The medium used for cultivating the chondrocytes was DME/F12 (Cat. No. 3-821-35, 
Imperial Laboratories Ltd. Andover, UK). The medium was a basal powder that was solved in 
500 ml sterile water (Cat. No. 883314, Pharmacia, Stockholm, Sweden) and supplemented 
with 2.2 g/l NaHCO3 (Cat. No. 1.06329.1000, Merck), 62 µg/ml ascorbic acid (Cat. No.A-
4034, Sigma, St.Louis, MO), and 50 µg/ml gentamycin (Cat. No. G-1264, Sigma). The 
mediums osmolality was adjusted to 290 nOsm/l using a cryoscopic osmometer (CryoStat, 
Gonotec GmbH, Berlin, Germany) and 280 µl H2SO4 (Merck, Darmstadt, Germany) was 
added. Finally the medium was sterile filtrated (0, 2 µM). 10 % autologous serum was added 
to the medium when cultivating the cells the first three weeks.  
 
The chondrocytes were stored in medium DME/F12 supplemented with 5 % Cryoserv (Baxter 
Research Medcal, Irvine, CA, USA) and kept in liquid nitrogen at -180 ºC. At the 
experimental start the cells were thawed and the cryopreservative was removed by two 
consecutive washings. The ampoule contents were transferred to sterile tubes with warm 
medium supplemented with 10 % foetal calf serum (Cat. No. 14-830L, Lonza, Medprobe, 
Norway), and the pellet was resuspended in fresh medium after centrifugation at 200 g. 
Finally the cells was resuspended in 5 ml fresh medium after the second wash, and transferred 
to 250 ml culture vessels (Cat. No. 3108, Falcon, BD Bioscience, Stockholm, Sweden) kept in 
humidified air containing 5 % CO2. Cultures were further expanded by trypsination (Cat. No 
T-3924, Sigma), and transferred to 500 ml culture vessels (Falcon). Experiments were 
performed when an appropriate cell number was achieved as judged by microscopy.  
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3.3 Reverse Transcriptase Polymerase Chain reaction (RT-PCR) 
Poly A mRNA from chondrocytes was extracted with Qiagen Direct mRNA kit (Merck 
Eurolab, Oslo, Norway). cDNA was synthesised by using SuperScript Preamplification 
System (Life Technologies Ltd., Paisley, UK) and was treated with 0.1 unit/l Escherichia coli 
RNase H at 37 ºC for 20 min.  
 
PCR was performed in a 50 µl reaction mixture containing cDNA (derived from 0,5 g 
mRNA), 150 nM of each primer, master mix containing taq polymerase, dNTPs, MgCL and 
buffer (5 Prime MasterMix, Cat.no. PRME2200100, VWR, Oslo, Norway) and ultra pure 
distilled water (10977-035, Gibco, Invitrogen, Oslo, Norway). The PCR were performed at 
94ºC for 5 min (first denaturation), then at 94ºC for 30 sec (denaturation), 55ºC for 30 sec 
(annealing) and 72ºC for 1 min (extension) for a total of 30 cycles with a 10 min final 
extension at 72ºC. All reactions were run using a Perkin-Elmer GeneAmpPCR system 2400 
(Perkin-Elmer, Cambridge, UK)  
 
Primers: 
Nucleotide sequences of PCR primers were designed to detect domains of the human 
ChemR23 receptor: 
Forward ChemR23  5´-TGG TCT ACA GCA TCG TC-3´  
Revers ChemR23 5´-ATG GCT GGG GTA GGA AGA GT-3´  
PCR product length 917-bp [38] 
 
To test the quality of the mRNA, the presence of APRT-gene transcripts was assayed. With 
the primers used, contaminating DNA would generate an 800-bp fragment, while mRNA 
would generate a 300-bp fragment: 
Forward APRT 5´- CCC GAG GCT TCC TCT TTG GC-3´ 
Reverse APRT 5´-CTC CCT GCC CTT AAG CGA GG-3´ 
PCR product length 300-bp [39] 
 




PCR products were analyzed by polyacrylamid gel (Novex TBE gel 6 % Cat no. 
EC6265BOX, Invitrogen, Norway), stained with SYBR-safe DNA gel stain (Cat. No S33102, 
Invitrogen) and photographed under UV-light using a G-BOX (Syngene, Cambridge, UK). 
 
3.4 Immunocytochemistry 
Identification of the ChemR23 receptor on serially cultured chondrocytes was performed with 
polyclonal rabbit anti-human ChemR23 antibody (Cat. No.ab13172, Abcam, Cambridge, 
UK). Chondrocytes were grown on fibronectin coated chamber slides (Cat No. 154534, Nunc, 
Roskilde, Denmark) for 24 hours. The cultures were washed twice with PBS (phosphate 
buffered saline) and fixated for 2 hours in cold PBS containing 0.2 M sucrose and 4 % 
paraformaldehyde. After fixating the cells the slides were blocked for one hour with PBS 
containing 1 % BSA (Bovine Serum Albumine, Cat No.A2153-10G, Sigma-Aldrich, Sweden 
AB, Stockholm, Sweden). After blocking, the slides were washed twice with PBS and 
primary antibody diluted 1:250 was added. The slides were incubated in primary antibody 
overnight at 4ºC. Then the slides were washed three times in PBS and secondary antibodies 
were added to sections at dilution 1:200 (Alexa fluor 488 conjugated goat anti-rabbit IgG, Cat 
No. A-11008 and Alexa fluor 568 conjugated goat anti-rabbit IgG, Cat. No. A-11011, 
Invitrogen), and incubated for 1 hour in room temperature. Negative controls were arranged 
by omitting primary antibody in respective sections. The slides were mounted by adding 
Dapi-fluoromount-G (Cat. No. 0100-20, SouthernBiotec, Birmingham, US) and examined in a 
Zeiss axiophot photomicroscope (Carl Zeiss, Oberkochen, Germany) equipped with Nikon 
Coolpix 995 digital camera. 
 
3.5 Immunohistochemistry 
Sections of a cartilage biopsies were made to study whether ChemR23 was present in native 
tissue. Paraformaldehyde (4 %) containing 0.2 M sucrose in PBS was used as fixative, and 
after 48 hours the biopsy was embedded in paraffin and sectioned at 5 µm thickness onto 
poly-L-Lysine-coated slides (0,01 %, Sigma-Aldrich). Sections were deparafinized by xylene 
and graded alcohol washes, and immersed in distilled water. Thereafter sections were 
incubated in PBS containing 1 % bovine serum albumin for 30 min followed by incubation 
with  monoclonal mouse anti-human chemerin antibody diluted 1:100 (Cat. No. MAB362, 
R&D systems, UK) overnight at 4ºC. After rinsing in PBS, sections were incubated for 45 
min with secondary antibody which were rabbit anti-mouse antibody conjugated with 
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horseradish peroxidase (HRP). SuperPicTure Polymer detection kit was used (Zymed 
Laboratories, San Francisco, CA, USA). A matched isotype was used as a control for 
nonspesific background staining. 
 
3.6 Western blotting of phospho-p44/42 MAPK (ERK1/2) and phospho-Akt 
Intracellular signal transduction triggered by Chemerin was investigated by immunoblotting 
of phosphorylated p44/42 (Thr202/Tyr204) and phosporylated Akt (Ser473) by using 
phospho-Erk1/2 pathway sampler kit (Cat. No. 9911, Cell Signaling Technology, US). 
Antibodies raised in rabbit towards phospho-p44/42 (Thr202/Tyr204) and phospho-Akt 
(Ser473) were used to detect ChemR23 mediated phosphorylation of the respective 
molecules.  
 
Cell cultures were arranged in three main groups; one group was challenged with recombinant 
Chemerin (Cat. No. 2324-CM, R&D systems, UK) and incubated in different time intervals. 
One group represented the control where only PBS was added, and the third was incubated 
with MEK1/2 inhibitor (Cat.No 9900, Invitrogen) and Chemerin. MEK 1/2 inhibitor was 
added to the cell culture one hour prior to stimulation with Chemerin. 0.5 x106 cells were 
added to each well in a 6 multiwell plate (Cat. No. 3046, Falcon) and grown in culture 
medium with 10 % FCS for 24 hours. Subsequently the cells were washed twice in PBS and 
incubated for 24 hours in culture medium without FCS. The next day cultures were washed 
twice and challenged with 10 nM chemerin for 1 min, 2.5 min, 5 min and 10 min. The wells 
were washed with PBS and harvested directly in 150 µl SDS-buffer containing NuPAGE LDS 
sample buffer ( Cat. No. NP0007, Invitrogen), NuPAGE Reducing agent (Cat. No. NP 0004, 
Invitrogen), phosphatase inhibitor (Cat. No. 78420, Thermo Scientific, Rockford, US), 
protease inhibitor (Cat.No. 04693124001, Roche, Indianapolis, US), and distilled water. 
 
The samples were heated to 100ºC for 5 min. 15 µl of each extract including 15 µl of a 
prestained protein marker (Cat. No. 7720, Cell Signaling Technology, US) to control the 
efficacy of the electrophoresis, and 10 µl of a biotinylated protein ladder (Cat. No. 7727, Cell 
Signaling Technology, US) to assess molecular weights (kDa) of proteins, was separated by 
electrophoresis in NuPAGE Mes SDS running buffer (Cat. No. NP 0002, Invitrogen) at 200V 
(constant), using 100-125 mA per gel (NuPAGE 4-12 % BIS-tris gels, Cat. No. NP0323, 
Invitrogen) for 35 minutes. Electroblotting was performed by electrontransfer onto PVDF-
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membranes (Cat. No. LC2005, Invitrogen) in NuPAGE transfer buffer (Cat. No. NP0006, 
Invitrogen) with 10 % methanol, at 30V (constant), using 170 mA per gel transfer for 1 hour. 
After electroblotting the membranes were blocked with 5 % non-fat dry milk/0,1 % Tween 20 
for 1 hour at room temperature. Thereafter the membranes were incubated in primary 
antibodies overnight at 4ºC in 5 % BSA/0,1 % Tween 20. The phospho-
p44/42(Thr202/Tyr204) antibody was used in a 1:2000 dilution, while the phospho-
Akt(Ser473) antibody was diluted 1:1000. Then the membranes were washed in wash buffer 
and incubated with HRP (Horseradish preoxidase)-conjugated goat anti-rabbit IgG (Cat.No 
7074, Cell Signaling Technology) and HRP-conjugated anti-biotin antibody (Cat. No. 7075, 
Cell Signaling Technology) for 1 hour in room temperature. Finally the proteins were 
detected by adding substrate containing Lumiglo reagent and Peroxide (Cat. No. 7003, Cell 
Signaling Technology) and developed with Fujifilm LAS-3000.  
 
3.7 Cytokine measurement 
Chondrocytes (0.5x106 cells) were added to three wells in a 6 well multiplate (Cat. No. 3046, 
Falcon) and incubated for 24 hour in culture medium with 10 % FCS. Thereafter the cells 
were washed twice with PBS and incubated 24 hours in culture medium with 0.1 % FCS. 
Thereafter the wells were washed twice and one well was added 1 ml of medium with 10 nM 
Chemerin, the second was added 1 ml medium with 100 nM Chemerin, and the third was 
added medium with PBS to represent the control. All cultures were incubated for 24 hours, 
before the medium supernatant was aliqouted and frozen in -70ºC for later experiment.   
 
One ampule of each medium supernatant was thawed on ice, and the levels of the cytokines 
TNF-, IL-1, IL-6 and IL-8 was measured using a 4-plex cytokine assay (Cat No. 
X50053UVBS, Bio-Rad, Hercules, CA, USA) using the analyser Bio-plex 200 system (Bio-
Rad,). The samples were run in a 1:4 dilution in duplicates.  
 
3.8 MMP measurement 
Chondrocytes (0.5x106 cells) were added to three wells in a 6 well multiplate (Cat. No. 3046, 
Falcon) and incubated for 24 hour in culture medium with 10 % FCS. Thereafter the cells 
were washed twice with PBS and incubated 24 hours in culture medium with 0.1 % FCS. 
Thereafter the wells were washed twice and one well was added 1 ml of medium with 10 nM 
Chemerin, the second was added 1 ml medium with 100 nM Chemerin, and the third was 
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added medium with PBS to represent the control. All cultures were incubated for 48 hours, 
before the medium supernatant was aliqouted and frozen in -70ºC for later experiment.   
 
One ampoule of each medium supernatant was thawed on ice, and the levels of the MMPs 
MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12 and MMP-13 was measured 
using a MMP-panel assay (Cat. No. LMP000, LMP901, LMP902, LMP513, LMP907, 
LMP908, LMP911, LMP919, LMP511, R&D) using the analyser Bio-plex 200 system (Bio-












































Cultured cells from two individuals were analysed separately for transcripts for the Chemerin 
receptor ChemR23. The cDNA detected by gel electrophoresis show that the mRNA 
corresponding to the 917 bp transcript of the ChemR23 was detected in both cell cultures 
(Fig. 7, lane 5 and 6). The APRT primers gave two bands with 300 bp length which indicated 
no contamination of genomic DNA in the two samples (Lane 2 and 3). Both negative controls 
(Lane 4 and 7) were negative. This result demonstrates that cultured chondrocytes produce 
transcripts for ChemR23. 
 
 







Figure 7: RT-PCR analysis of the expression of Chemerin receptor ChemR23 in cultured human 
articular chondrocytes. Lane 2 and 3: APRT primers were run with cDNA from two different 
cell cultures. The 300 bp bands show that the APRT transcript is generated from mRNA. Lane 
4: APRT primers + water. Lane 5 and 6: ChemR23 primers were run with cDNA from two 
different individuals. The 917 bp bands indicate transcripts for the Chemerin receptor. Lane 7: 
ChemR23 primers + water. Lane 8: APRT primers were run with genomic DNA to show the 800 







Micrographs of cultivated chondrocytes showed a positive staining in presence of primary 
antibody compared to the unstained controls (Fig. 8). We used one primary antibody and two 
different secondary Alexa fluor conjugated antibodies to visualize the receptor, and both 
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Figure 8: Cultured human articular chondrocytes stained with polyclonal rabbit anti-human 
ChemR23. Micrograph A show positively stained chondrocytes using antibody conjugated with 
Alexa fluor dye 488. Micrographs B represent the same picture but here the nuclei of the 
chondrocytes are visualized by Dapi dye. Micrograph C and D show positively stained 
chondrocytes using Alexa fluor 568 (C), and visualized nuclei by Dapi (D). Micrographs E and F 





Sections of cartilage tissue showed positively stained chondrocytes in the presence of primary 




Figure 9: Sections of human articular cartilage tissue (400X) stained with monoclonal mouse 
anti-human ChemR23. Micrograph A show positively stained chondrocytes (brown staining). 
Micrograph B show unstained chondrocytes and represent the negative control where the 
primary antibody was replaced with a matched IgG isotype antibody to check for unspecific 
binding.    
 
 
4.3 Western blotting for phospho-p44/42 (ERK 1/2) and phospho-Akt 
In Western blot studies of cultured chondrocytes challenged with 10 nM Chemerin for 1 min, 
2.5 min, 5 min and 10 min, bands occurred where anti-phospho-p44/42(Thr202/Tyr204) were 
used (Fig.10 ). In lane 1 representing unstimulated cells, a band also occurred and indicated a 
background of phosphorylated p44/42. The bands occurring after stimulating with Chemerin 
for 5 and 10 minutes were denser, showing a higher activation of the p44/42 MAPK as a 
result of ChemR23 activation by Chemerin. In lane 2, the MEK1/2 pathway was inhibited and 
this could be seen by weak bands, showing reduction of phosphorylated p44/42. These results 




In a paralleled experiment, detecting phospho-Akt (Ser473) by Western blot, bands occurred 
where anti-phospho-Akt (Ser473) was used (Fig.11). In unstimulated cells (Lane 1), there 
was a weak band present, indicating a low background level of phospho-Akt. The bands 
occurring after stimulating with Chemerin shows that phosho-Akt levels increases from the 
unstimulated sample to 5 minute of challenge with Chemerin, and then decreases after 10 
minutes of challenge. These results demonstrate that Chemerin activation of ChemR23 
increases phosporylation of Akt which may induce activation of MEK1/2 (Fig. 12). This 














Figure 10: Western blotting of phosphorylated p44/42 (Thr202/Tyr204)  
Following starvation for 24 hours, human chondrocytes were challenged for 1 min (Lane 3), 2.5 
min (Lane 4), 5 min (Lane 5) and 10 minutes (Lane 6) with 10 nM recombinant Chemerin. For 
the visualization of phospho-p44/42, rabbit anti-human-phospho-p44/42 was used. Bands can be 
seen in lane 3, 4, 5 and 6 and the density increases after 5 and 10 minutes. Lane 1 represents the 
control where no Chemerin was added. The band observed in this lane indicates background 
phosphorylation of p44/42. Lane 2 represents the sample extract where the MEK 1/2 kinase 
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Figure 11: Western blotting of phosphorylated Akt (Ser473) 
For the visualization of phospho-Akt, rabbit-anti-human-phospho-Akt (Ser473) was used. Bands 
in lane 3-6 represent cell cultures challenged with 10 nM chemerin for 1, 2.5, 5 and 10 minutes 
and indicate that the phosphorylation of Akt increases with increased stimulation time and 
decreases around 10 minutes of stimulation. Lane 1 represents the negative control and shows a 
low background phosphorylation of Akt. Lane 2 represent the culture where the MEK 1/2 was 






Ref: http://www.cellsignal.com/pdf/9911.pdf  
 
Figure 12: Overview of the MAPK signalling pathway  
Phosphorylated Akt can activate the MEK 1/2 pathway by phosphorylatin c-Raf. MEK 1/2 
activates the MAP-kinases p44/42 (Erk 1/2) by phosphorylation of the amino acids threonine 202 
and tyrosine 204.  
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4.4 Cytokine measurement 
The measurement of cytokines in supernatants from chondrocytes challenged with Chemerin, 
showed an increased concentration of TNF-, IL-1, IL-6 and IL-8 compared to the 
unstimulated control (Table 1). IL-6 and IL-8 were markedly increased compared to IL-1 
and TNF-, and the cytokine levels were increased in a dose-dependent manner. These results 
demonstrate that Chemerin stimulates cultivated chondrocytes to produce pro-inflammatory 
cytokines.  
 
Table 1: Cytokine levels in supernatants from three individual chondrocyte cultures challenged 
with chemerin in vitro for 24 hours. 
Cytokine   Unstimulated 10 nM Chemerin 100 nM Chemerin 
TNF-  Patient 1 710 727 880 
pg/ml 2 747 741 840 
  3 154 222 245 
IL-1 Patient 1 147 154 187 
pg/ml 2 158 156 179 
  3 30 44 48 
IL-6 Patient 1 2572 29352 41010 
pg/ml 2 28410 32429 34264 
  3 4010 5617 6707 
IL-8 Patient 1 19937 20715 53255 
pg/ml 2 31849 32191 49448 




4.5 MMP measurement 
The measurement of eight different MMPs in supernatants from three individual chondrocyte 
cultures challenged with Chemerin, showed an increased concentration of MMP-2, MMP-3 
and MMP-13 compared to the unstimulated control (Table. 2). A marked increase of all three 
MMPs was observed for two of the patient samples, while a modest increase of the three 
MMPs was observed for the third patient. These results show that Chemerin induces the 







Table 2: MMP levels in supernatants from three individual chondrocyte cultures challenged 
with chemerin in vitro for 48 hours. 
    Unstimulated 
10 nM 
Chemerin 100 nM Chemerin 
MMP-1 Patient 1 64857 63947 72501 
pg/ml 2 73125 68601 74293 
  3 45797 54196 71109 
MMP-2 Patient 1 182813 164869 270921 
pg/ml 2 91327 92796 109885 
  3 97634 99084 320164 
MMP-3 Patient 1 477649 456698 899049 
pg/ml 2 506769 432008 598323 
  3 50442 54571 204657 
MMP-7 Patient 1 112 97 162 
pg/ml 2 295 368 474 
  3 107 115 156 
MMP-8 Patient 1 109 81 81 
pg/ml 2 702 702 969 
  3 43 29 146 
MMP-9 Patient 1 84 94 94 
pg/ml 2 953 795 866 
  3 68 85 70 
MMP-12 Patient 1 <15 <15 <15 
pg/ml 2 <15 <15 <15 
  3 <15 <15 <15 
MMP-13 Patient 1 8391 7828 19276 
pg/ml 2 927 837 1003 



















Rheumatic diseases are abundant and a large group of the population is affected. Rheumatoid 
Arthritis occurs in about 1 % of the population [22] and in the US, 70 % of the population 
between the age 55-78 have evidence of OA [2]. Considering the increasing lifespan of 
humans, arthritis will be a growing public health problem, involving large costs for the 
society [40]. To days treatment of arthritis is mainly based on anti-inflammatory therapy, pain 
relief and surgery in cases where the joint destruction is comprehensive. A lot of effort has 
been taken to understand the inflammatory process in joint diseases, and a better 
understanding has led to the development of several drugs against pro-inflammatory 
cytokines, like TNF- blockers, with varying effects [41]. Although medication dampens 
symptoms, they do not necessarily prevent the disease progression [4]. It has been shown that 
arthritis may develop many years before any symptoms occur, but the lack of diagnostic tools 
makes the possibility for preventive treatment difficult [42, 43]. Recent findings have shifted 
the attention to the chondrocytes, and their role in the deterioration of cartilage matrix. It is 
clear that the chondrocytes are not completely isolated in the cartilage matrix, but actively 
participates in cell signalling in the joint [5]. There is evidence that the chondrocytes 
themselves are partly responsible for the deterioration of cartilage matrix, and the fact that 
cartilage destruction may occur without clinical signs of inflammation renders them a target 
for preventive treatment [7].  
 
Cartilage destruction is mainly a result of imbalance in the cartilage metabolism. The features 
are often a shift in the balance between degrading proteases (MMPs) and the inhibitors of 
these proteases, Tissue Inhibitor of Metalloproteinases (TIMPs). This can be caused by pro-
inflammatory mediators or by increased apoptosis/necrosis of chondrocytes which results in 
impaired matrix maintenance [44]. Our research group has previously demonstrated the 
presence of soluble TRAIL (TNF Related Apoptosis Inducing Ligand) in synovial fluid from 
inflamed joints, with levels up to150 pg/ml (unpublished data). We have further identified the 
TRAIL receptors DR4, DR5 and DCR2 on cultivated chondrocytes [45]. Soluble TRAIL 
binds DR4 and DR5 and induces apoptosis in chondrocytes. In 2002 we showed that 
chondrocytes express functional leptin receptors and that the activation by leptin induces cell 
proliferation and promotes matrix synthesis [39]. Results from several other research groups 
support our findings and the fact that chondrocytes can produce and bind a variety of 
cytokines and chemokines [1, 25, 27].  
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Previous results show that chondrocytes express several immune receptors, including class II 
histocompatibility antigens (MHC-II), which indicates immunregulatory activity by 
chondrocytes [46]. The present results further emphasize the role of chondrocytes in 
inflammatory diseases, as we here show that chondrocytes express Chemerin receptors. This 
is evident by the findings that chondrocytes produce ChemR23 transcripts, and that the 
receptor is present on chondrocytes in native cartilage and in vitro. The receptor binds 
recombinant Chemerin to elicit intracellular signalling leading to phosphporylation of ERK 
1/2 and Akt, both being central signal transduction pathways for various inflammatory and 
metabolic responses [47, 48]. By stimulating cultured chondrocytes with Chemerin we show 
that ChemR23 conveys pro-inflammatory signalling in chondrocytes by stimulating the 
production of the pro-inflammatory cytokines IL-8 (Interleukin 8) and IL-6 (Interleukin 6), 
and affects cartilage metabolism by inducing the production of MMPs. Furthermore, it 
appears that Chemerin can exhibit dual effects in inflamed joints by attracting cells of the 
immune system to the inflamed joints [19], and at the same time bind to ChemR23 on 
chondrocytes and initiate a pro-inflammatory cytokine production. Our results show 
similarities with the discovery of the Chemerin receptors on adipocytes, and the ability of 
Chemerin to induce inflammation in adipose tissue [32, 33]. Hence, it can be suggested that 
Chemerin and ChemR23 have a role in the initiation of inflammation in cartilage tissue as 
well.  
 
In addition to a marked elevation in IL-6 and IL-8 production, stimulation of chondrocytes 
with recombinant Chemerin also resulted in a modest increase of TNF- and IL-1. These 
results are consistent with reports showing elevated levels of these cytokines in adiponectin 
stimulated chondrocytes [1], and in synovial fluid from RA patients [49]. Several clinical 
observations have suggested a possible role for cartilage as a primary source of pro-
inflammatory stimuli, as inflammatory responses often develops rapidly after traumatic 
cartilage injury [27]. Our results may portray a role of ChemR23 in the initiation of 
inflammation by chondrocytes as IL-8 is a potent chemokine witch exerts chemotacic activity 
towards neutrophils [50]. By this way, activation of the ChemR23 on chondrocytes indirectly 
attracts neutrophils by initiating the production of IL-8. This process may have implications in 
the development of chronic inflammation in joint disease. 
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Elevated production of IL-6 in supernatants from Chemerin stimulated chondrocytes was also 
observed, and Guerne et al. have previously showed that chondrocytes produce IL- 6 in 
response to physiologic and inflammatory stimuli, and that IL-6 may serve as a mediator to 
coordinate responses to cartilage injury [51]. IL-6 modulates the growth and differentiation of 
B- [52] and T-lymphocytes [53], and our findings may indicate that ChemR23 signalling can 
contribute to the activation of B- and T-cells in joint inflammation through IL-6.  
 
IL-1 and TNF- are characterized as the main drivers of cartilage and bone erosion [4]. 
Although we did not observe any significant elevation of these two cytokines, it might be that 
these mediators are produced mainly by immune cells and synovial cells as a result of 
inflammatory stimuli. These mediators may bind receptors on chondrocytes and stimulate the 
MMP production, thus affecting cartilage metabolism indirectly [54]. Furthermore, despite the 
modest increase in IL-1 and TNF- , these levels may be sufficient to have a significant 
effect in the inflammatory process. Reports show that these cytokines together have strong 
synergistic effects at low concentrations [4]. TNF- drives the acute inflammation, whereas 
IL-1 has a role in sustaining both inflammation and cartilage erosion [55]. Our results show 
that Chemerin stimulates TNF-  and IL-1 production by chondrocytes, which can initiate 
inflammation in joint diseases.   
 
In arthritis, excessive degradation of cartilage matrix components by proteinases is main 
features of the destructive process. Depletion of proteoglycans from articular cartilage is a 
common initial change in joint disease with subsequent degradation of the collagen fibrils 
[56]. Our results show an increase in the production of the matrix metallo proteinases MMP-
2, MMP-3 and MMP-13 in supernatants from Chemerin stimulated chondrocytes. These 
results are consistent with previously reports showing production of the these MMPs by 
chondrocytes in vitro [57-61]. The three MMPs we observed in the present study, all cleave 
the major proteoglycan aggrecan at the Asn373 –Phe342 bond (the MMP site), and the two 
major aggrecan fragments from cleavage of the respective sites, are detected in the joint fluid 
from patients with various arthritic diseases [62]. MMP-13 also selectively digests type II 
collagen which becomes denatured into gelatine. Gelatine is further digested into smaller 
peptides by gelatinases (MMP-2 and MMP-9) [63, 64].These observations supports our idea 
that ChemR23 plays a pivotal role in cartilage destruction, and our results show that Chemerin 
stimulates the production of MMPs in chondrocytes, and thus may portray a connection 
between inflammation initiation and cartilage deterioration.  
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According to earlier reports, the production of IL-8, IL-6 and MMPs in chondrocytes are 
assigned to the action of TNF- and IL-1 [17, 27, 51, 65, 66]. The altered levels of IL-6, IL-
8, MMP-2, MMP-3 and MMP-13 in our experiments, appears to be ChemR23-mediated. 
However, Chemerin may have induced a rapid increase of TNF- and IL-1 at an early phase 
after stimulation, and the levels of IL-6, IL-8 and MMPs may be delayed products from 
autocrine actions on chondrocytes by TNF- and IL-1. Considering the 24 and 48 hours of 
Chemerin challenging, the cytokines may have peaked early during cultivation and thereafter 
been degraded or internalized. The different levels of cytokines and MMPs observed between 
the three individuals may reflect varying activation status in the cells during the cell 
preparations. Still, all the cultures showed an increase in cytokine/MMP quantity when 
challenged with Chemerin.   
 
The source of Chemerin in synovial fluid is not yet identified, but Chemerin may enter the 
synovial fluid from the circulation through the capillaries surrounding the joint. Another 
possibility is that chondrocytes produce pro-Chemerin themselves. Considering how 
cytokines can act on their producer cells in an autocrine fashion, it may be that chondrocytes 
secrete pro-Chemerin which is then activated by neutrophil-derived proteases in the synovial 
fluid during inflammation. 
 
As previously described, chemokines control immune cell trafficking, and infiltration of 
leukocytes is a hallmark of many autoimmune and chronic inflammatory diseases. For this 
reason approaches to prevent cell recruitment to inflamed tissues may be exploited, like 
preventing the effect of chemotactic mediators such as chemokines. Because cytokines 
mediate the production of chemokines, blocking the effect of chemokines has been done 
indirectly by blocking the biological effects of cytokines. This has been demonstrated by anti-
TNF- antibodies such as Remicade® and Humira®, souble TNF- receptors such as 
Enbrel®, IL-1 receptor anatagonist Kineret®, anti-IL-6 receptor MRA®, and the anti-IL-15 
antibody HuMax-IL-15®. Since cytokine and cytokine receptor reactions are complex, 
targeting specific actions has proven to be difficult and more attention is now given to 
chemokines that bind GPCRs. Several drugs currently marketed are either agonists or 
antagonists of GPCRs, i.e. these receptors have proven to be potent targets [21]. 
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Developing antagonists against chemokine receptors has not yet been successful and this may 
be explained by the muliple functions of chemokines; a particular chemokine may bind 
several chemokine receptors and many chemokines may bind a single chemokine receptor. 
These features are characterized by different affinities between receptor and ligand, and 
activation of different signalling pathways [21]. A chemokine may act either as an agonist or 
an antagonist, depending on the receptor it binds [67, 68]. An example is the chemokine 
CXCL11, which is an agonist of a receptor mainly expressed on T helper type 1 (Th1) cells, 
while it acts as an antagonist on a receptor expressed on T helper type 2 (Th2) cells. This way 
the chemokine may attract Th1 cells to sites of injury, and simultaneously suppress the 
trafficking of Th2 cells to the same site. Despite the difficulties in developing antagonists to 
chemokine receptors, there is still intense activity in the field, and a number of agents are 
currently in development [69, 70].   
 
Studies of inflammation has confirmed that the resolution process is an active process 
involving a pro-resolving signalling network [71, 72]. By measuring inflammatory exudates 
Serhan and colleagues have described lipid mediators that exhibit anti-inflammatory 
properties [73, 74]. These resolution-phase mediators use omega-3 polyunsaturated fatty acids 
as precursors to generate agonists for promoting resolution by reducing further recruitment of 
leukocytes. The omega-3 polyunsaturated fatty acids eicosapentaenoic (EPA) and 
docosahexaenoic acid (DHA), are independently converted to resolvins and protectins [72]. 
Representatives of each family of lipid mediators, lipoxins from aracidonic acid (AA), 
resolvin E1 from EPA and neuroprotectin D1 from DHA, act at different steps in defined 
resolution indices, and are anti-inflammatory when given in vivo [71]. One member of the 
resolvin family, RvE1, is an aspirin triggered lipid mediator. Aspirin acetylates 
cyclooxygenase-2 (COX-2) and through the action of acetylated COX-2  and lipoxygenase 
(LO), EPA is converted into RvE1 through cell to cell interactions [73]. RvE1 has proven to 
be a strong anti-inflammatory and pro-resolving mediator, and reduces polymorphonuclear 
leukocyte (PMN) transendothelial migration and release of superoxide in the nanomolar 
concentration range [73, 75]  These actions are also demonstrated in vivo, where RvE1 blocks 
PMN infiltration in peritonitis [76] and in inflamed colon tissue during colitis in mouse [77]. 
RvE1 actions on PMNs can be explained by the binding of RvE1 to the leukotriene B4 
receptor (BLT1). RvE1 interacts with BLT1 as a partial agonist serving as a local damper of 
leukotriene B4 (LTB4)-BLT1 signals in PMNs, thus inhibiting PMN migration [76].   
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Arita et al. showed in 2005 that RvE1 binds both the LTB4 receptor, BLT1 and the Chemerin 
receptor, ChemR23 [76]. This way RvE1 attenuates APC functions by targeting DC migration 
and by reducing IL-12 production through ChemR23. Arita et al. further showed that RvE1 
bound and activated ChemR23 to block TNF-a signalling, thus RvE1 mediate counter 
regulatory actions against ChemR23 to promote resolution. Compared to our result showing 
the expression of ChemR23 on chondrocytes, RvE1 may exibit similar actions on 
chondrocytes, making RvE1 a potential antagonist to Chemerin actions. Considering RvE1 
actions on leukocytes it would be interesting to study whether RvE1 could both attenuate 
leukocyte recruitment into inflamed joints and at the same time prevent pro-inflammatory 
signalling in chondrocytes, thus preventing cartilage degradation. These studies are currently 
in progress in our research group. 
 
Conclusion 
The results presented in this thesis demonstrate the presence of a receptor previously not 
described on human articular chondrocytes, ChemR23. This receptor transduces intracellular 
signals through MAP kinases and Akt signalling pathways when challenged with Chemerin in 
vitro. It appears that activation of the receptor conveys pro-inflammatory signalling based on 
the findings demonstrating an increased pro-inflammatory cytokine production and MMP 
secretion. These results suggest that ChemR23 may have a pivotal role in cartilage destruction 
and the initiation and persistence of joint inflammation. Blocking ChemR23 from binding 
Chemerin may reduce inflammation in the joint. The receptors pro-inflammatory action 
renders it a potential therapeutic target and its ability to bind RvE1 renders ChemR23 to be a 
promising candidate for pro-resolution signalling. However, further studies are needed to 
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A1. PCR Protocol 
Equipment: 
5 Prime MasterMix (Cat.no. PRME2200100, 5 prime, VWR international, Oslo, Norway) 
Perkin-Elmer GeneAmpPCR system 2400 (Perkin-Elmer, Cambridge, UK) 
 
Remember to preheat the PCR block  
• Make the working solution of all the primers to be 1000 nM from the stock: 
 Stock primers for ChemR23: 100 uM 
 Stock primers for APRT: 100 uM 
• Working solution 1000 nmol/L: 
 100 000 nmol/L x X = 1000 nmol/L x 500 ul X = 5 ul 
 Solve 5 ul of each primer in 495 ul distilled water 
• Thaw the mastermix and mix well 
• Prepare PCR tubes 
• Mix the different templates/primers in sterile 0,2 ml tubes and adjust the volume with 
water:  
Component Reaction volume 
50 ul 
End concentration 
Master mix (Taq, dNTP, 
Mgcl, buffer) 
20ul  
Template/primer mix 30 ul  
Forward primer  7,5 ul 100-200 nM 
Reverse primer 7,5 ul 100-200 nM 
Template DNA 3 ul cDNA 
Water 12 ul  
 
• First add the correct volume of master mix to each PCR tube. 
• Then add the template/pimer mix to each tube. Mix without making bubbles and place 
the tubes on ice.   
• Run the PCR reaction; Denaturing temp: 94 ºC. Annealing temp 55 ºC at 30 cycles.  
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• After the run, the PCR may be visualized by gel electrophoresis, ore stored in the 
freezer for later analyzes.   
 
Sample layout: 
Sample 1: Mastermix + APRTF + APRTR + cDNA1 + H2O 
Sample 2: Mastermix + APRTF + APRTR + cDNA2 + H2O 
Sample 3: Mastermix + APRTF + APRTR + H2O 
Sample 4: Mastermix + ChemR23F + ChemR23R + cDNA1 + H2O 
Sample 5: Mastermix + ChemR23F + ChemR23R + cDNA2 + H2O 
Sample 6: Mastermix + ChemR23F + ChemR23R + H2O 
Sample 7: Mastermix + APRTF + APRTR + Genomic DNA + H2O 
 
 
A1.1 PCR-product visualization 
Equipment: 
Novex TBE gel 6% (Invitrogen cat no. EC6265BOX) 
Xcell surelock mini-cell (Invitrogen cat no. EI0001) 
Powerease 500 power supply (Invitrogen cat no. EI8700) 
TBE running buffer 5X (Invitrogen cat no. LC6675) 
High density TBE loading buffer 5X (Invitrogen cat no. LC6678) 
PCR marker (Novagen cat no. 69278-3) 
SybrSafe (Cat. No S33102, Invitrogen, Norway 
G-BOX (Syngene, Cambridge, UK) 
  
• Make the TBE running buffer 1000 ml: 200 ml 5xTBE + 800 ml deionised wather 
• Unwrap and prepare a gel: Take out one gel and rinse with water. Remove the tape 
from the back of the gel. Remove the well comb and wash the wells three times with 
running buffer. Place the gel in the upper buffer chamber. 
• Install the electrophoresis chamber: fill the upper chamber with 200 ml running buffer 
and the lower chamber with 600 ml running buffer. 




15 ul PCR product 
 5 ul sample loading buffer 
 5 ul deionized water        
 25ul Total volume 
 
Well:  1: 5 ul Marker 
  2: 25 ul sample  
  3: 25 ul sample 2     
  4: 25 ul sample 3 
  5: 25 ul sample 4 
  6: 25 ul sample 5 
  7: 25 ul sample 6 
  8: 25 ul sample 7 
  9: 5 ul Marker 
 
• Place the lid to the chamber and connect the power supply. 
• Choose a pre-maid program for TBE gels on the “power ease 500” and press start. 
• After the run; incubate the gel in SybrSafe solution for 30 minutes.  














A2. Immunecytochemistry protocol 
Equipment: 
Lab-TekII chamber slides (Cat. No. 154534 Nunc, VWR international, Norway) 
Fibronectin (Cat. No. F4759, SigmaAldrich) 
Fixation buffer (PBS with 0,2 M sucrose + 4% paraformaldehyd) 
ChemR23 antibody ( Cat. No.ab13172, Abcam, Cambridge, UK) 
Secondary antibodies (Alexa fluor 488 goat anti-rabbit IgG, Cat No. A-11008 and Alexa fluor 
568 goat anti-rabbit IgG, Cat. No. A-11011, Invitrogen, Oslo, Norway) 
Dapi-Fluoromount-G (Cat. No. 0100-20, SouthernBiotech) 
 
Day 1: 
• Coat one slide with fibronectin by covering the slide with fibronectin solution, remove 
all excess liquid and let the slide dry up.  
• Wash the slide with 200 ul PBS in each well. 
• Make 2 ml growth medium with 5 % FCS: 2000 ul medium + 100 ul FCS 
• Add 400 ul of the growth medium to each well of the slide. Add 20 ul of the cell 
suspensjon to each well. Check in the microscope to see if the cell number is 
preferable.   
• Incubate the slides in a cell incubator for 24 hours. 
 
Day 2: 
• Wash the cells carefully two times with PBS 
• Fixate the cells by adding 200 ul cold fixation buffer and incubate the slide for 1 hour 
in 4 ºC.  
• Wash the slide two times 
• Add 200 ul PBS with 1% BSA to each well and incubate for 1 hour. 
• Wash the slide two times 
• Add 200 ul primary antibody (1:250) to each well exept for the two control wells. 
Incubate the slide over night at4 ºC. Add 200 ul PBS to the control well 
Slide layout: 
Primary antibody:  Rabbit anti-human chemR23 1:250 
Secondary antibody:  Goat anti- rabbit IgG alexa fluor 488 1:250 





















• Wash the slide two times 
• Add 200 ul secondary antibody (1:200) and incubate the slide in 1 hour in room 
temperature. 
• Wash three times 
• Remove all the wells and Add Dapi-Fluromount-G before covering the slide with a 
cover glass 
• Let the slide set for 30 minutes 
• Microscope the slides  
 
A3. Western blotting protocol 
Equipment: 
Electrophoresis: Xcell surelock Mini-cell (Cat. No. EI0001 Invitrogen) 
Blotting module: XCell II Blot module (EI9051 Invitrogen) 
NuPAGE MESS DS buffer kit (Cat. No. NP0060, Invitrogen) 
Halt Phosphatase inhibitor coctail (Cat. No.78420, Thermo) 
Protease inhibitor (Cat.No. 04693124001, Roche, Indianapolis, US) 
Hepatocytometer 
MEK 1/2 inhibitor (Cat. No. U0126, Cell Signaling) 
Recombinant chemerin (Cat. No. 2324-CM, R&D) 




• Remove the medium from cultivated chondrocytes 
• Add 5 ml PBS and wash the cells 
• Remove the PBS 
• Repeat step 2 and 3 
• Add 1 ml trypsin, and watch the cell in the microscope to see if they have loosened.  
• Add 5 ml medium with 10% FCS and transfer the suspension to a 15 ml tube for 
centrifugation. 
• Centrifuge for 5 min in 1500 RPMI, remove the supernatant and add 5 ml of new 
medium 
• Count the cells to determine the cell number:  
   Burkers counting chambre: 1E square correspond to 1/250 ul = 0,004 ul 
   The chamber consists of 144 E squares and this correspond to 0,576 ul 
 
 Count 10 E squares:  
 Cell count per square:   N/10  
 Cell count per ul:   (N/10)  = celles/ul 
      0,004 ul   
 Total cell count:   celles/ul x volume of cell suspension in ul 
 
• Transfer the amount of ul that accounts for 0.5 x 106 cells to each well with total of 6 
wells. Add fresh medium with 10 % FCS to a total wolume of 3 ml. Incubate the cells 
over night.  
 
Day 2 
• Remove the medium from each well and wash carefully with PBS. Add 3 ml fresh 
medium without FCS. Incubate the cells overnight. 
 
Day 3 
• Remove the medium in one well and add 10 uM MEK 1/2 inhibitor in 2 ml medium 
one hour prior to the stimulation 
• Remove the medium in all the wells except the inhibitor well, and add the chemerin 
and medium to its respective wells (see cell stimulation protocol further down) 
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• Remove the medium and stimuli at the different time intervals and wash once with 
PBS.  
• Remove all liquid before the sample buffer is added 
• Add the sample buffer and reducing agent directly into the wells:  
 
Add 150 ul 1x sample buffer with 100mM DTT to each well:  
240 ul Sample buffer 4x + 720 ul deionised water 
 
Add DDT to a  1X concentration  = 1 ul per 10 ul 
960 ul / 10 = 96 x 1 = 96 ul DDT 
96 ul DDT 10x + 864 ul sample buffer 1X 
 
Add 10 ul phosphatase inhibitor cocktail and 20 ul protease inhibitor cocktail to the 
sample buffer before adding it to the wells. 
 
• Scrape the wells and collect the fluid into 1.5 ml tubes on ice 
• Sonicate the tubes in 10-15 seconds 
• Centrifuge the tubes for 10 min at 14 000 rpm, collect the supernatant for use. 
 
A3.1 Cell stimulation for western blot  
MEK1/2 Inhibitor: 
Stock: 10 mM 
Final concentration in on well with a total volume of 2 ml:   
2 ml x 10 umol/l = X x 10 000 umol/l 
X = 0,002 ml = 2 ul 
 
Chemerin  
Stoch: 25 ug 
Solve in 1 ml PBS with 0,1% BSA = 25ug/ml = 0,025 mg/ml = 0,025 g/l 
Mw = 16 000 g/mol  
Stock will be: 
0,025 g/l = 0,00000156 M = 0,00156 mM 
16000 g/mol 
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Make 9 ml of a 10 nM chemerin solution: 
9 ml x 0,00001 mmol/l = X x 0,00156 mmol/l 
X = 0,0576 
X = 57,6 ul 
Add 58 ul Chemerin stock to 8,95 ml medium without serum 
 
Plate layout: 
Well 1: Control 
2000 ul medium + 12,8 ul 
PBS/0,1 % BSA 
Well 2: MEK1/2 3 min 
2000 ul medium/Inhibitor + 
12,8 ul stock chemerin 
Well 3: 1 min 
2000 ul medium/ 10 nM 
chemerin 
Well 4: 2,5 min 
2000 ul medium/ 10 nM 
chemerin 
Well 5: 5 min 
2000 ul medium/ 10 nM 
chemerin 
Well 6: 10 min 






NuPAGE Novex 4-12 % Bis-Tris gels 15 brønner (Cat. No. NP0323, Invitrogen) 
Prestained protein marker (Cat. No. 7720 CellSignaling) 
Biotinylated protein ladder (Cat. No. NP 7727 cellsignaling)  
Running buffer (Cat. No. NP 0002 Invitrogen) 
Antioxidant (Cat. No. NP0005 Invitrogen) 
 
• Make 1 litre of 1x Running buffer: 50 ml 20x running buffer + 950 ml deionised water 
• Open one gel and rinse with water 
• Remove the comb from the wells and wash the wells three times with running buffer.  
• Remove the gel tape 
• Set up the gel in the electrophoresis chamber.  
• Fill the inner upper chamber with 200ml running buffer and add 500ul antioxidant 
• Fill the lower chamber with 600 ml running buffer 
• Boil the samples and ladders at 95-100 ºC for 3 min 
• Add samples and ladders to their respective wells 





1 Prestained ladder 15 ul 
2 Biotinylert ladder 10 ul 
3 Test 0 min 15 ul 
4 MEK 1/2 Inhibitor 
5 Test 1 min 15 ul 
6 Test 2,5 min 15 ul 
7 Test 5 min 15 ul 
8 Biotinylert ladder 10 ul 
 
 
A3.3 Blotting procedure 
Equipment: 
PVDF membrane 0,45uM (Cat. No. LC2005 Invitrogen) 
NuPAGE transfer buffer 20x (Cat.No. NP0006 Invitrogen) 
Methanol 
 
• Make 1x transfer buffer: 50 ml 20x transfer b + 100 ml methanol + 849 ml deionised 
water + 1 ml antioxidant 
• Prepare the PVDF- membrane:  
• wet the membrane in methanol 
• rinse in water 
• incubate the membrane in transfer buffer for minimum 5 min 
• Open the gel-cassette and remove the wells 
• Place a pre-wet filter paper on the gel and flip the gel into your hand, resting on the 
filter-paper.  
• Remove the lower part of the gel so it loosens from the cassette.   
• Wet the gel with transfer buffer and place the PVDF membrane on the gel followed by 
a filter-paper. Remove air bubbles 
• Place to pre-wet blotting pads into the cathode (-) in the blotting module.  
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• Place the gel and the membrane with the filter-papers over the pads, with the gel 
resting closest to the cathode.  
• Place two pre-wet blotting pads over the gel and membrane. 
• Place the anode (+) on top 
• Place the hold module in the electrophoresis chamber 
• Fill the module chamber with transfer buffer  
• Fill the outer chamber with 650 ml of water 
• 16. Run the electro-blotting 
   
A3.4 Detection 
Equipment: 
Phototope-HRP WB detection system (Cat. No. 7071 CellSignaling) 
Phospho-Erk1/2 Pathway sampler kit (Cat. No. 9911 Cell Signaling) 
TBS buffer: Tris Base, NaCL 
Blocking buffer: Tween, fat fri dry-milk, 
Wash buffer (TBS + tween) 
 
Make the reagents: 
 
TBS buffer 10X 250 ml: 
6,05 g Tris base 
20 g NaCL 
250 ml milliQ 
 
Adjust pH to 7,6 buy using HCl 
 
TBS buffer 1X 250 ml: 
25 ml 10X TBS buffer 
225 ml MilliQ water 
 
Blocking buffer 50 ml: 
5 ml 1X TBS 
45 ml MilliQ water 
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2,5 g dry milk (non fat) 
0,05 ml (50 ul) Tween-20(100 %) 
 
Wash buffer 100 ml: 
0,1 ml (100 ul) Tween-20  0,1 % = (100 x 0,1)/100 = 0,1 ml 
100 ml TBE 1X 
 
Primary Antibody dilution buffer 20 ml: 
2 ml 10X TBS 
18 ml MilliQ water 
1.0 g BSA 
20 ul Tween-20 (100 %) 
 
• After blotting, wash the membrane in 5 ml 1x TBS in 5 minutes 
• Incubate the membrane in 10 ml blocking buffer for one hour 
• Wash 3x5 min in 5 ml wash buffer 
• Incubate the membrane with 10 ml primary antibody over night at 4 ºC  
 
Dilution phospho-p44/42 MAPK antibody, 42,44 kDa:  1:2000 in 10 ml = 5 ul Ab  
Dilution phospho-Akt antibody, 60 kDa   1:1000 in 10 ml = 10 ul Ab 
Add 15 ul total of the two antibodies in 10 ml dilution buffer 
 
Day 4 
• Remove he primary antibodies and wash 3x5 min in wash buffer 
• Add the secondary antibodies in 10 ml blocking buffer and incubate for one hour in 
room temperature.  
Anti-Rabbit IgG HRP-linked antibody:    1:2000 in 10 ml = 5 ul Ab 
Anti-Biotin HRP linked:     1:1000 in 10 ml = 10 ul i Ab 
Add 15 ul total of the two antibodies in 10 ml dilution buffer 
 
• Wash 3x 5 min in 5 ml wash buffer 
• Add 5 ml LumiGLO ( 250ul 20X LumiGlo + 250ul 20x Peroxide + 4,5 ml milliQ 
water)  
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• Mix for 1 minute 
• Rap the membrane in plastic and develop the membrane 
 
A4. Cytokine measurement protocol 
A4.1 Cell stimulation 
Day 1 
• Remove the medium from cultivated chondrocytes 
• Add 5 ml PBS and wash the cells 
• Remove the PBS 
• Repeat step 2 and 3 
• Add 1 ml trypsin, and watch the cell in the microscope to see if they have loosened.  
• Add 5 ml medium with 10% FCS and transfer the suspension to a 15 ml tube for 
centrifugation. 
• Centrifuge for 5 min in 1500 RPM, remove the supernatant and add 5 ml of new 
medium 
• Count the cells to determine the cell number:  
   Burkers counting chamber: 1E square correspond to 1/250 ul = 0,004 ul 
   The chamber consists of 144 E squares and this correspond to 0,576 ul 
 
 Count 10 E squares:  
 Cell count per square:   N/10  
 Cell count per ul:   (N/10)  = celles/ul 
      0,004 ul   
 Total cell count:   celles/ul x volume of cell suspension in ul 
 
• Transfer the amount of ul that accounts for 0.5x106 cells to each well with total of 3 
wells. Add fresh medium with 10 % FCS to a total volume of 3 ml. Incubate the cells 
over night.  
 
Day 2 
• Remove the medium from each well and wash carefully with PBS. Add 3 ml fresh 




•  Remove the medium from all wells and wash once with PBS 
•  Add Chemerin and medium to its respective wells (se plate layout further down) 
•  Incubate the plate for 24 hours 
 
Day 4 
•  Harvest the cellsupernatants and centrifuge the tubes for 5 min at 10 000 RPM to 
remove cell fragments 





Well 1: Control 
Cells + 1000 ul medium with 
PBS/0,1 % BSA 
Well 2: 10 nM  
Cells + 1000 ul medium/10 
nM chemerin 
Well 3: 100 nM 








A4.2 Quantitatively determination of cytokines 
Equipment: 
Bio-plex cytokine assay (Cat No. X50053UVBS, Bio-Rad, Hercules, CA) 
Bio-plex 200 system (Bio-Rad, Hercules, CA) 
 
• Solve the standard: The standard has to be solved in the same matrix as the samples.  
Add 500 µl cell growth medium, vortex gently for a few seconds and leave the 
standard on ice for 30 min. 
• Prepare the samples: 
 The samples should be run at a 1:4 dilution 
 1 : 4:  30µl cell sample + 90µl diluent 
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• Make the standard curve: 
Standard values for standard 1 is printed in the std package. The standard dilution is 
1:4 
 Std 1: 128 µl stock + 72 µl medium 
 Std 2: 50µl std1 + 150µl medium 
 Std 3: 50µl std2 + 150µl medium 
 Std 4: 50µl std3 + 150µl medium 
 Std 5: 50µl std4 + 150µl medium 
 Std 6: 50µl std5 + 150µl medium 
 Std 7: 50µl std6 + 150µl medium 
 Std 8: 50µl std7 + 150µl medium 
 Std 9: 50µl std 8 + 150µl medium 
 
• Pre-wet the 96-well plate: 
 Add 100µl assay buffer to each ell  
• Remove the buffer by vacuum 
• Add 50 ul of  the assay beads to each well  
• Remove the liquid by vacuum and wash the beads twice in wash buffer 
• Add standards and samples in their respective wells.  
• Seal the plate with plastic, wrap it in foil and incubate on a plate shaker at 300 RPM 
for 45 min 
• Turn on the Bio-Plex machine and prepare for running the plate.  
• Dilute the detection antibody: 
 
Detection Antibody (10x)  
Wells  
10x Stock Detection 
Antibody (l)  
Detection Antibody 
Diluent A (l)  Total Volume (l)  
96  300  2,700  3,000  
48  150  1,350  1,500  
32  100  900  1,000  
24  75  675  750  
 
• Wash the plate three times by adding 100 ul wash buffer 
• Add 25 ul of detection antibody to each well and incubate the plate in foil on a plate 
shaker for 30 min 









• Wash the plate three times by adding 100 ul wash buffer 
• Add 50 ul of strepdavidin-PE to each well and incubate the plate in foil for 10 minutes 
on a plate shaker. 
• Wash the plate three times by adding 100 ul wash buffer 
• Add 125 µl assay buffer to each well 
• Shake the plate for 1 minute, then analyze the plate 
 
 
A5. MMP-panel measurement protocol 
A5.1 Cell stimulation 
Day 1 
• Remove the medium from cultivated chondrocytes 
• Add 5 ml PBS and wash the cells 
• Remove the PBS 
• Repeat step 2 and 3 
• Add 1 ml trypsin, and watch the cell in the microscope to see if they have loosened.  
• Add 5 ml medium with 10% FCS and transfer the suspension to a 15 ml tube for 
centrifugation. 
• Centrifuge for 5 min in 1500 RPM, remove the supernatant and add 5 ml of new 
medium 
• Count the cells to determine the cell number:  
   Burkers counting chamber: 1E square correspond to 1/250 ul = 0,004 ul 













96 60 5 940 6 000
48 30 2 970 3 000
32 20 1 980 2 000
24 15 1 485 1 500
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 Count 10 E squares:  
 Cell count per square:   N/10  
 Cell count per ul:   (N/10)  = celles/ul 
      0,004 ul   
 Total cell count:   celles/ul x volume of cell suspension in ul 
 
• Transfer the amount of ul that accounts for 0.5x106 cells to each well with total of 3 
wells. Add fresh medium with 10 % FCS to a total volume of 3 ml. Incubate the cells 
over night.  
Day 2 
• Remove the medium from each well and wash carefully with PBS. Add 3 ml fresh 
medium with 0.1 % FCS. Incubate the cells overnight. 
 
Day 3  
•  Remove the medium from all wells and wash once with PBS 
•  Add Chemerin and medium to its respective wells (se plate layout further down) 
•  Incubate the plate for 48 hours 
 
Day 5 
•  Harvest the cellsupernatant from the 48 hours incubation plate, centrifuge the tubes for 
5 min at 10 000 RPM to remove cell fragments 






Well 1: Control 
Cells + 1000 ul medium with 
PBS/0,1 % BSA 
Well 3: 10 nM 
Cells + 1000 ul medium/10 
mM chemerin 
Well 2: 100 nM  







A5.2 Quantitatively determination of MMP 
Equipment: 
Human Base Kit MMP panel Fluorokine MAP (Cat. No. LMP000, R&D) 
8 Different Human MMP Fluorokine MAP (Cat. No. LMP901, LMP902, LMP513, LMP907, 
LMP908, LMP911, LMP919, LMP511). 
 
• Prepare the wash buffer 
• Solve the standard in 0,9 ml of calibrator diluent RD5-37 and let it sit for 15 min on 
ice 
• Mix the bead buffer: add 25 ul of each bead buffer (25 ul x 8) into 2300 ul 
microparticle diluent 
• Prepare the samples: 
 The samples should be run at a 1:4 dilution 
 1:4:  30µl cell sample + 90µl calibrator diluent RD5-37 
• Make the standard curve: 
Standard values for standard 1 are printed in the package. The standard dilution is 1:3 
 Std 1: 500 µl stock 
 Std 2: 100µl std1 + 200µl Calibrator diluent 
 Std 3: 100µl std2 + 200µl Calibrator diluent 
 Std 4: 100µl std3 + 200µl Calibrator diluent  
 Std 5: 100µl std4 + 200µl Calibrator diluent 
 Std 6: 100µl std5 + 200µl Calibrator diluent 
 Std 7: 100µl std6 + 200µl Calibrator diluent 
   
• Pre-wet the 96-well plate: 
 Add 100µl assay buffer to each ell  
• Remove the buffer by vacuum 
• Add 50 ul of  the assay beads to each well  
• Add standards and samples in their respective wells.  
• Seal the plate with plastic, wrap it in foil and incubate on a plate shaker at 500 RPM 
for 2 hours 
• Turn on the Bio-Plex machine and prepare for running the plate.  
 59 
• Dilute the detection antibody: Add 50 ul of each antibody into the bottle with ready 
antibody diluent 
• Wash the plate three times by adding 100 ul wash buffer 
• Add 50 ul of detection antibody to each well and incubate the plate in foil on a plate 
shaker for 60 min 
• Dilute the Streptavidin-PE: 27,5 ul streptavidin + 2750 ul wash buffer 
• Wash the plate three times by adding 100 ul wash buffer 
• Add 50 ul of strepdavidin-PE to each well and incubate the plate in foil for 30 minutes 
on a plate shaker. 
• Wash the plate three times by adding 100 ul wash buffer 
• Add 100 µl assay buffer to each well 
• Shake the plate for 1 minute, then analyze the plate 
 
 
 
 
 
 
 
 
 
 
 
 
